Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways

Biochemical Pharmacology

Volumn 74, Issue 3, 2007, Pages 407-414

  Khalilzadeh, Azita ^a   Wangoo, Kiran T ^a   Morris, David L ^a   Pourgholami, Mohammad H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Albendazole; ALL; Apoptosis; Leukemia; Paclitaxel; Resistance

Indexed keywords

ALBENDAZOLE; CASPASE 3; CYTOCHROME C; EPOTHILONE DERIVATIVE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DEPOLYMERIZATION; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME RELEASE; HUMAN; HUMAN CELL; IC 50; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SENSIBILITY; T LYMPHOCYTE; TREATMENT RESPONSE;

ALBENDAZOLE; APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DNA PRIMERS; EPOTHILONES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250774576     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.006     Document Type: Article

References (42)

1. Pui C.H., and Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 339 (1998) 605-615
2. Verrills N.M., Flemming C.L., Liu M., Ivery M.T., Cobon G.S., Norris M.D., et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 10 (2003) 597-607
3. Myrick D., Blackinton D., Klostergaard J., Kouttab N., Maizel A., Wanebo H., et al. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk Res 23 (1999) 569-578
4. Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 8 (1997) 17-25
5. Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55 (1995) 2325-2333
6. Kowalski R.J., Giannakakou P., and Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272 (1997) 2534-2541
7. De Silva N., Guyatt H., and Bundy D. Anthelmintics: a comparative review of their clinical pharmacology. Drugs 53 (1997) 769-788
8. Ireland C.M., Gull K., Gutteridge W.E., and Pogson C.I. The interaction of benzimidazole carbamates with mammalian microtobule protein. Biochem Pharmacol 28 (1979) 2680-2682
9. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 121 Suppl (2000) S113-S132
10. Pourgholami M.H., Akhter J., Wang L., Lu Y., and Morris D.L. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55 (2005) 425-432
11. Pourgholami M.H., Yan Cai Z., Lu Y., Wang L., and Morris D.L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12 (2006) 1928-1935
12. Meyer L.H., Karawajew L., Schrappe M., Ludwig W.D., Debatin K.M., and Stahnke K. Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. Blood 107 (2006) 4524-4531
13. Vistica D.T., Skehan P., Scudiero D., Monks A., Pittman A., and Boyd M.R. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 51 (1991) 2515-2520
14. Savli H., Sirma S., Nagy B., Aktan M., Dincol G., and Ozbek U. Real-time PCR analysis of the apoptosis related genes in ATRA treated APL t(15;17) patients. Exp Mol Med 35 (2003) 454-459
15. Faucher K., Rabinovitch-Chable H., Cook-Moreau J., Barriere G., Sturtz F., and Rigaud M. Overexpression of human GPX1 modifies Bax to Bcl-2 apoptotic ratio in human endothelial cells. Mol Cell Biochem 277 (2005) 81-87
16. Andersen M.H., Becker J.C., and Thor Straten P. The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 19 (2005) 484-485
17. Pellegrini F., and Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23 (2005) 264-273
18. Ganansia-Leymarie V., Bischoff P., Bergerat J.P., and Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 3 (2003) 291-306
19. Hersey P., Zhuang L., and Zhang X.D. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 251 (2006) 131-158
20. Springer J.E., Nottingham S.A., McEwen M.L., Azbill R.D., and Jin Y. Caspase-3 apoptotic signaling following injury to the central nervous system. Clin Chem Lab Med 39 (2001) 299-307
21. Wang J., and Lenardo M.J. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 113 Pt 5 (2000) 753-757
22. Rosse T., Olivier R., Monney L., Rager M., Conus S., Fellay I., et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391 (1998) 496-499
23. Amos C.L., Woetmann A., Nielsen M., Geisler C., Odum N., Brown B.L., et al. The role of caspase 3 and BclxL in the action of interleukin 7 (IL-7): a survival factor in activated human T cells. Cytokine 10 (1998) 662-668
24. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
25. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
26. Chao D.T., and Korsmeyer S.J. Bcl-2 family: regulators of cell death. Annu Rev Immunol 16 (1998) 395-419
27. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3 (1997) 614-620
28. Reed J.C. Double identity for proteins of the Bcl-2 family. Nature 387 (1997) 773-776
29. Kolfschoten G.M., Hulscher T.M., Duyndam M.C., Pinedo H.M., and Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 63 (2002) 733-743
30. Makin G.W., Corfe B.M., Griffiths G.J., Thistlethwaite A., Hickman J.A., and Dive C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. Embo J 20 (2001) 6306-6315
31. Haldar S., Jena N., and Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92 (1995) 4507-4511
32. Reed J.C. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7 (1995) 541-546
33. Srivastava R.K., Mi Q.S., Hardwick J.M., and Longo D.L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96 (1999) 3775-3780
34. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., and Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4 (1993) 327-332
35. Manion M.K., Fry J., Schwartz P.S., and Hockenbery D.M. Small-molecule inhibitors of Bcl-2. Curr Opin Investig Drugs 7 (2006) 1077-1084
36. Yoshino T., Shiina H., Urakami S., Kikuno N., Yoneda T., Shigeno K., et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12 (2006) 6116-6124
37. Kozopas K.M., Yang T., Buchan H.L., Zhou P., and Craig R.W. Mcl-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90 (1993) 3516-3520
38. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91 (1998) 991-1000
39. Hemann M.T., and Lowe S.W. The p53-Bcl-2 connection. Cell Death Differ 13 (2006) 1256-1259
40. Reed J.C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9 (1995) 451-473
41. Rafki N., Liautaud-Roger F., Devy L., Trentesaux C., and Dufer J. P53 protein expression in human multidrug-resistant CEM lymphoblasts. Leuk Res 21 (1997) 147-152
42. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55 (1993) 678-684